Lupine Publishers | LOJ Pharmacology & Clinical Research
Abstract
A
breakthrough, Multiple Mixed Strain Probiotic Therapy, although originally
designed to cure hospital acquired infections, has been discovered
serendipitously by Dr. M.S. Reddy to treat cancer with greatest accuracy (60%
as opposed to current 20%), with least or no side effects and least or no
relapse, when used as an adjuvant therapy along with standard cancer therapies,
including immune checkpoint therapy. This discovery can be further refined and
improved to treat cancer at 80 to 100% efficacy to save lives of millions of
people in the world by significantly improving immune system through positive
manipulation of the human gut microbiota and their microbiome. The results of
the clinical trials are outlined along with discussion and conclusion. The references
listed have been limited to the latest, significant, and directly applicable
research discoveries only.
Keywords: Dr MS Reddy’s multiple mixed strain
probiotic therapy to treat hospital acquired infections; Nosocomial infections;
Dr MS Reddy multiple mixed strain adjuvant cancer therapy; Microbiota; Hospital
acquired infections; Immune checkpoint therapy; C Diff; MRSA; Microbiome
Introduction
A
brief history on statistics of the cancer episode in the world. The
International agency for Research on Cancer (IARC), a division of The World
Health Organization (WHO), estimated that the global cancer epidemic rose to
18.1 million new cases and 9.6 million deaths in 2018 alone. The IARC reports 1
in 5 men (20%) and 1 in 6 women (16.66%) worldwide develop cancer during their
lifetime. 1 in 8 men (12.5%) and 1 in 11 women (9.09%) die from the disease. In
addition, every sixth death in the world is due to cancer. Assuming world
population is 7 billion and assuming the ratio of male to female is 50:50, 700
million men and 583 million women will develop cancer during their life time
and 437 million men and 318 million women will die of cancer. These figures are
astronomical, mind blowing, and downright scary, unless something is done to
prevent or cure cancer efficiently with 100 percent accuracy, without any
relapse.
Materials, Methods, and Discussion
The
question here is, how did Dr. M.S. Reddy’s discovery to treat cancer came about
serendipitously? In the year 2016, Dr. M.S. Reddy, after working extensively
for four decades on probiotics, published a breakthrough research article on
the usage of Multiple Mixed Strain Probiotic Therapy to treat or prevent the
hospital acquired or nosocomial infections caused by Clostridium difficile (C.
diff), and Methicillin Resistant Staphylococcus Aureus (MRSA) [1-4]. He has
isolated and selected the strains of Probiotics which are naturally resistant
to several antibiotics and sulfonamides to use in this discovery. Dr. M.S.
Reddy has studied and confirmed through thorough research that, the antibiotic
resistance was not coded by the plasmids but by the chromosol genes, thus it is
safer to use these Multiple Mixed Strain Probiotics to eliminate the free
exchange of plasmids to the pathogenic bacteria [5]. The Multiple Mixed Strain
Probiotic Strains belonging to different genera and species (with varied
physiological characteristics) were grown separately in selected nutritionally
balanced media, not only to maximize their cell numbers and their single cell
morphology (as opposed to chain formation), but also to significantly improve
the quantity of their end products of growth i.e. immunomodulins, bacteriocins,
and specific and nonspecific bio-active peptides etc. Such individually grown
single strain probiotics were blended in fixed proportions and frozen using
liquid nitrogen, to be used as therapeutic agents administered through oral
route [3]. Unlike the popular thinking, the significant feature of the
discovery is that the probiotic bacterial cultures alone (without their prior
growth end products) did not cure the hospital acquired infections. However,
the multiple growth end products of these Multiple Mixed strain Probiotics
(immunomodulins) along with the active probiotic bacteria significantly cured
the nosocomial infections [6].
It
was also determined and confirmed that the multiple antibiotic resistant
pathogenic bacteria i.e. C. diff etc. was initially inhibited (in vivo) through
the immunodolation exerted by the Multiple Mixed Strain Probiotic growth end
products along with the dendritic cells picked up probiotic cell wall antigens.
The immunomodulation induced by probiotics was through production of IL-10,
retinoic acid, TGF-Beta with resultant well balanced activation of T-reg cells
[7]. The excess inflammation caused due to immune stimulation as a response to
the pathogenic bacterial peptides of C. diff bacteria, through activation of
Th-1, Th-2, Th-17 and excess production of IGA, was reduced predominantly
through activation of T-reg cells stimulated by Multiple Mixed Strain
Probiotics and their immunomodulins, used in this discovery [7]. As a second
step (after establishment of positive immunomodulation in vivo), the live
probiotic cells in the intestinal tract lumen started directly inhibiting the
pathogenic C diff organisms etc. Thus, this invention is novel in that the
primary inhibition of the pathogenic bacteria is indirectly due to the
previously produced active immunomodulins of the probiotic bacteria, followed
by the secondary direct physical inhibition due to live probiotic bacteria in
the Lumen, through nutritional competency, production of organic acids,
bacteriocins, and finally through stimulation and maintenance of component
balance of other non-pathogenic saprophytic intestinal microbiota [5,7]. The
bacteriological analysis of patient’s feces, after the multiple probiotic
infusion treatment, revealed total absence of pathogenic C. diff organisms, and
at the same time significant elevation of intestinal microbiota (in comparison
to the beginning of treatment) by two logs (determined by combination of
anaerobic as well as aerobic total bacterial counts). In addition, it was
proven that the individual strains used in the Multiple Mixed Strain Probiotic
Therapy did adhere to the intestinal epithelial cells of the host, which was
confirmed by biopsy and subsequent microbiological testing including strain
specific phage typing. While conducting the practical clinical trials using Dr.
M.S. Reddy’s Multiple Mixed Strain Probiotics to prevent or cure hospital
acquired infections, Dr. Reddy came up with another novel breakthrough
serendipitous discovery to cure cancer with a significantly greater efficiency,
when such Multiple Mixed Strain Probiotic Therapy is used as an adjuvant in
combination with standard cancer therapies, including the immune checkpoint
therapy. This breakthrough discovery has been published in 2018 [7]. Dr. M.S.
Reddy’s discovery is termed as “Dr. M.S. Reddy’s Multiple Mixed Strain
Probiotic Adjuvant Cancer Therapy”. This Adjuvant Cancer Therapy establishes
immune tolerance and thus helps the primary cancer therapy to be most
effective, with least or no side effects. It also significantly reduced the
relapse of cancer, which was proven through multiple community based clinical
trials. This was accomplished through positive maintenance of the cancer
patients gut microbiota and their microbiome, thus establishing the proper
immunomodulation which results in significant reduction of immune stimulation
and inflammation. This in turn established a positive immune tolerance, which
is the prime requisite to synergistically improve the efficiency of the
standard cancer therapies. This explains why most of the previous cancer
therapies were not effective to cure cancer with greater efficiency (of not more
than 20 percent).
The
clinical tests (with regard to treatment or prevention of nosocomial
infections) clearly proved the following, using the procedure outlined in our
earlier publication [1,5]. The antibiotic therapy (using vancomycin and
bacitracin) alone could not cure the hospital acquired infections; probiotic
therapy by itself showed significant progress even after one week treatment
followed by total cure by 4th week; prior administration of probiotics (prior
to hospitalization) for a period of 2 weeks, significantly reduced C. diff
infection; the subjects who were given preventive probiotics for a period of 3
weeks (prior to hospitalization) did not pick up any C. diff infection, during
and after hospitalization; combination of antibiotic and Multiple Mixed Strain
Probiotic Therapy cured the C. diff infection in two weeks compared to
probiotic therapy alone (which took 4 weeks) and antibiotic therapy alone
(which could not cure even after, and beyond 4 weeks of treatment). Although it
was a serendipitous discovery, later several planned community based clinical
trials conducted using Multiple Mixed Strain Probiotic Therapy as an Adjuvant
Cancer Therapy, along with the immune checkpoint therapy and other standard
cancer therapies, proved that cancer was cured with 60% efficiency, as opposed
to 20% by immune checkpoint therapy and other standard therapies alone. Unlike
the pharmaceutical cancer drugs, Multiple Mixed Strain Probiotics come under
nutritional supplements, as per the Code of Federal Regulations, and thus are
highly economical and affordable and can be used without any major governmental
regulations [2].
Conclusion
Dr.
Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, proven through
extensive basic research and continued multiple practical community based
clinical trials, found to be the best complementary therapy to cure cancer
along with the use of immune checkpoint therapy and other traditional cancer
therapies. Ultimately, this could be the answer to prevent or treat cancer with
80 to 100% accuracy with no immune related side effects and with least relapse.
Thus, cancer can be treated using such a complementary adjuvant probiotic
therapy, along with any chosen conventional cancer therapy, as a choice therapy
than a chance therapy, to save lives of over 9 million people in the world per
year. It is the first time in the world, where a missing link in the successful
treatment of cancer has been discovered, and immense credit should go to this
breakthrough medical discovery. This discovery can be further improved to
develop customized treatment by taking into account the genetics of the cancer
patients to cure several cancers. Multiple Mixed Strain Probiotic Therapy,
coupled with positive nutritional and life style modifications, may also serve
as a preventive aid to eliminate or reduce cancer epidemic by maintaining the
healthy microbiota and their microbiome.
https://lupinepublishers.com/pharmacology-clinical-research-journal/fulltext/genesis-evaluation-and-progression-of-a-breakthrough-discovery-to-efficiently-cure-cancer.ID.000121.php
https://lupinepublishers.com/pharmacology-clinical-research-journal/pdf/LOJPCR.MS.ID.000121.pdf
For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishersgroup.com/
For more Pharmacology & Clinical Research Please Click
Here: https://lupinepublishers.com/pharmacology-clinical-research-journal/
To Know more Open Access Publishers Click on Lupine Publishers
Follow on Linkedin : https://www.linkedin.com/company/lupinepublishers
Follow on Twitter : https://twitter.com/lupine_online
